FTH — Faeth Therapeutics, Share Price
Last trade - 00:00- $459.38m
- $256.60m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.4 | ||
| Price to Tang. Book | 2.4 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -97.1% | ||
| Return on Equity | -165.3% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. The Company's lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. The Company is also completing a Phase I/II trial of solnerstotug, its V-domain Ig suppressor of T cell activation (VISTA) inhibitor, in patients with advanced solid tumors. Its TMAb platform is designed to enable highly selective targeting through conditional antibody activation of immune cells in the tumor microenvironment without on-target, off-tumor activity. Its programs include Solnerstotug (SNS-101), SNS-102, SNS-103, and SNS-201. Solnerstotug is a conditionally active, human monoclonal IgG1 antibody designed to block the VISTA checkpoint, which acts as a suppressor of T cells by binding the receptor PSGL-1.
Directors
- John Celebi PRE (49)
- Erin Colgan SVF (40)
- Robert Pierce CSO (56)
- Marie-Louise Fjaellskog OTH (56)
- Anupama Hoey OTH (50)
- Kristian Humer DRC (46)
- Samuel Broder IND
- Bob Holmen IND (57)
- James Peyer IND (34)
- Thomas Ricks IND (67)
- Deneen Vojta IND (56)
- Last Annual
- December 31st, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- December 1st, 2017
- Public Since
- February 4th, 2021
- No. of Shareholders
- 193
- No. of Employees
- 29
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 25,778,754
- Address
- 701 Tillery Street #12 #1010, AUSTIN, 78702
- Web
- https://www.senseibio.com/
- Phone
- +1 2402438000
- Auditors
- Deloitte & Touche LLP
Latest News for FTH
Upcoming Events for FTH
Q2 2026 Sensei Biotherapeutics Inc Earnings Release
Q3 2026 Sensei Biotherapeutics Inc Earnings Release
Similar to FTH
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
As of Today at 20:35 UTC, shares in Faeth Therapeutics, are trading at . This share price information is delayed by 15 minutes.
Shares in Faeth Therapeutics, last closed at and the price had moved by +138.24% over the past 365 days. In terms of relative price strength the Faeth Therapeutics, share price has outperformed the S&P500 Index by +89.55% over the past year.
The overall consensus recommendation for Faeth Therapeutics, is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreFaeth Therapeutics, does not currently pay a dividend.
Faeth Therapeutics, does not currently pay a dividend.
Faeth Therapeutics, does not currently pay a dividend.
To buy shares in Faeth Therapeutics, you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of , shares in Faeth Therapeutics, had a market capitalisation of $459.38m.
Here are the trading details for Faeth Therapeutics,:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: FTH
Based on an overall assessment of its quality, value and momentum Faeth Therapeutics, is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Faeth Therapeutics,. Over the past six months, its share price has outperformed the S&P500 Index by +84.45%.
As of the last closing price of , shares in Faeth Therapeutics, were trading +8.61% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Faeth Therapeutics, PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at .
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Faeth Therapeutics,'s management team is headed by:
- John Celebi - PRE
- Erin Colgan - SVF
- Robert Pierce - CSO
- Marie-Louise Fjaellskog - OTH
- Anupama Hoey - OTH
- Kristian Humer - DRC
- Samuel Broder - IND
- Bob Holmen - IND
- James Peyer - IND
- Thomas Ricks - IND
- Deneen Vojta - IND